Dec 9 (Reuters) – Pfizer said on Tuesday it had entered into an exclusive licensing agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical, for the development and commercialization of an experimental weight management treatment.
(Reporting by Christy Santhosh in Bengaluru; Editing by Anil D’Silva)
